MissionIR Small-Cap Investor Blog: February 2023

Monday, February 27, 2023

MissionIRNewsBreaks – Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM) Begins Trading on Toronto Stock Exchange

Eloro Resources (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM) has obtained conditional approval to list its common shares on the Toronto Stock Exchange (“TSX”). According to the announcement, Eloro shares will trade under the trading symbol: ELO. The announcement also noted that the listing is subject to Eloro Resources fulfilling certain requirements of the TSX; those terms were outlined in a conditional approval letter that was dated Feb. 22, 2023. “This is a significant milestone for Eloro and its shareholders,” said Eloro Resources CEO Thomas Larsen in the press release. “The TSX is one of the world’s pre-eminent exchanges for mineral resource companies. A TSX listing will increase our visibility and profile in the capital markets and in the mining industry. Listing on the TSX will also offer benefits to shareholders such as enhanced market access for Canadian and international investors, increased access to capital and improved liquidity, as the company advances its flagship Iska Iska project in southern Bolivian.”

To view the full press release, visit https://ibn.fm/HyCvm

About Eloro Resources Ltd.

Eloro is an exploration and mine-development company with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec. Through its Bolivian subsidiary, Eloro has an option to acquire a 100% interest in the highly prospective Iska Iska Property, which can be classified as a polymetallic epithermal-porphyry complex, a significant mineral deposit type in the Potosi Department in southern Bolivia. A recent NI 43-101 technical report on Iska Iska, which was completed by Micon International Limited, is available on Eloro’s website and under its filings on SEDAR. Iska Iska is a road-accessible, royalty-free property. Eloro also owns an 82% interest in the La Victoria Gold/Silver Project, located in the north-central mineral belt of Peru, some 50 kilometers south of Barrick’s Lagunas Norte Gold Mine and Pan American Silver’s La Arena Gold Mine.

NOTE TO INVESTORS: The latest news and updates relating to ELRRF are available in the company’s newsroom at https://ibn.fm/ELRRF

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Golden Matrix Group Inc. (NASDAQ: GMGI) Releases Q1 Financial Report with Record $10.5M Revenues

Golden Matrix Group (NASDAQ: GMGI), a developer, licensor and global operator of online gaming and eCommerce platforms, systems, and gaming content, is reporting record revenues for its first quarter, ending Jan. 31, 2023. The report shows that revenues reached more than $10.5 million for the quarter, an estimated 19% improvement on $8.8 million revenues for the same quarter last year and a 10% increase over $9.57 million revenues for the previous quarter. Additional financial results for the quarter will be available in GMGI’s quarterly report on 10-Q filing, which should be filed on or before March 15, 2023. “Our new fiscal year is off to a great start, with the first quarter in our Company’s history to record more than $10 million in revenues,” said Golden Matrix Group CEO Brian Goodman in the press release. “Our core business-to-business platform for operators throughout the Asia Pacific region remains strong, and we are now seeing an acceleration of growth in the company’s business-to-consumer segment, UK-based RKings Competitions Ltd. . . . Improvements in marketing, customer acquisition costs and operating efficiencies at RKings are paying off as evidenced by the B2C platform’s enhanced performance. Additionally, we believe we have positioned RKings’ highly scalable platform to be introduced into other regions, beginning with Mexico this year.”

To view the full press release, visit https://ibn.fm/6XSx7

About Golden Matrix Group Inc.

Golden Matrix Group, based in Las Vegas, Nevada, is an established B2B and B2C gaming technology company operating across multiple international markets. The B2B division of Golden Matrix develops and licenses proprietary gaming platforms for its extensive list of clients and RKings, its B2C division, operates a high-volume eCommerce site enabling end users to enter paid-for competitions on its proprietary platform in authorized markets. The company’s sophisticated software automatically declines any gaming or redemption requests from within the United States, in strict compliance with current U.S. law. For more information about the company, visit www.GoldenMatrix.com

NOTE TO INVESTORS: The latest news and updates relating to GMGI are available in the company’s newsroom at https://ibn.fm/GMGI

About MissionIRNewsBreaks

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Plan to Streamline Efforts, Maximize Efficiency, Focus on Clinical Trials

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has announced a strategic plan designed to streamline efforts, maximize operating efficiency and focus on critical clinical trials, including near-term, mid-term and long-term milestones. A part of that plan was the release of an estimated 15% of Cybin’s workforce, including those in roles that were identified as not a clinical priority or not directly involved with any clinical trial initiatives. This move alone is expected to generate cost savings by reducing operating expenses. The announcement noted that with the anticipated cost savings from the overall streamlining efforts combined with Cybin’s ongoing and previously announced $35 million At-the-Market (“ATM”) equity program, the company will be better positioned for both near-term and long-term success. The announcement observed that Cybin has evolved from discovery-stage to clinical-stage operations, necessitating a clinical alignment designed to leverage intellectual property generated from its discovery efforts for clinical development and focus on clinical execution.

“The company has made the prudent decision to evaluate every role within its workforce, including whether certain tasks could be performed more efficiently while ensuring that the company’s core clinical activities continue to be robustly supported and resourced,” said Cybin CEO Doug Drysdale in the press release. “We appreciate the significant contributions of our employees and the hard work they performed for the company and understand the impact that this difficult decision has on them. We are committed to maintaining a lean organization and will continue to make clinical trial execution in support of our proprietary molecules our top priority.”

To view the full press release, visit https://ibn.fm/bzgxD

About Cybin Inc.

Cybin is a leading ethical biopharmaceutical company working with a network of world-class partners and internationally recognized scientists on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. The company is focused on progressing Psychedelics to Therapeutics(TM) by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About MissionIRNewsBreaks

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF) CEO Joins Investor Webinar, Details Corporate Expansion Plans

EverGen Infrastructure CEO, Chase Edgelow recently joined a webinar hosted by Adelaide Capital to provide investors and stakeholders with an update on the company’s operations
Edgelow elaborated on the company’s portfolio, including its 4 existing revenue generating assets, 2 projects currently under construction as well as its Ontario-based Greenfield project, Project Radius
By 2Q 2023, EverGen anticipated that the completion of its RNG projects would drive gross generating capacity to 240,000 GJ/annum, whilst growing EBITDA by $5-7m per year
In the longer term, successful execution on EverGen’s Ontario-based Greenfield project could see the company expand its RNG production by as much as 1.7 million GJ/year

British-Columbia based natural gas operator, EverGen Infrastructure (TSX.V: EVGN) (OTCQX: EVGIF), has long held aspirations of transforming into Canada’s leading RNG infrastructure platform, in the process securing strong long-term contracted cash flows. The company today operates 4 revenue generating assets across 3 key regions in Canada, alongside 2 RNG projects currently under construction as well as one Ontario-based project in development. EverGen Infrastructure Corp CEO, Chase Edgelow recently participated in a webinar hosted by Adelaide Capital to provide investors with an update on the company’s ongoing operations as well as their prospects going forward (https://ibn.fm/XPI4q).

Edgelow revealed that following the completion of its two RNG projects currently under construction, namely Fraser Valley Biogas and GrowTEC, both of which are anticipated to be ready as of the end of Q1 2023–EverGen Infrastructure will see its built-up capacity expanded to 240,000 gigajoules of RNG per annum, a growth which could drive an additional $5-7 million dollars worth of EBITDA per year for the company. Meanwhile and on a longer-term basis, EverGen is simultaneously pursuing the expansion of all its ongoing projects through a broad-based $45m pre-funded capital expenditure plan; successful completion of all its initiatives will see the company grow its cumulative gross generating capacity to 480,000 gigajoules of renewable natural gas on an annual basis, whilst simultaneously tripling EverGen’s current run-rate EBITDA.

Over 37 billion tons of carbon emissions are released into the world’s atmosphere on a yearly basis (https://ibn.fm/uMUVl); in one recent study, BNY Mellon estimated that over $100 trillion in investments was necessary to tackle emissions if the world was to successfully achieve its stated Net Zero ambitions by 2050 (https://ibn.fm/XMRTj). Today and with over $1 trillion being invested annually into building out clean energy capacity (https://ibn.fm/0MS7Z), EverGen Infrastructure Corp finds itself operating at the center of what former Bank of England Governor, Mark Carney, referred to as the “greatest commercial opportunity of our age.”

EverGen Infrastructure’s path to becoming one of Canada’s largest RNG platforms owes its origins to the province of British Columbia’s decision in March 2017 to amend the Greenhouse Gas Reduction Regulation. The amendment, which sought to increase the production and use of renewable gas as well as green and waste hydrogen in British Columbia to simultaneously generate jobs and economic opportunities while reducing GHG emissions, has played a significant role in driving the sector’s growth prospects in recent years.

Since starting its operations and expanding its presence in British Columbia to three operating assets, EverGen Infrastructure made a bold decision to expand its presence nationwide over the past year. In 2022, the company broadened its Canadian footprint by acquiring a 67% stake in GrowTEC, an Alberta-based biogas project. EverGen would subsequently go on to purchase a 50% ownership in a large joint venture consisting of three high-quality, on-farm RNG projects in Ontario dubbed Project Radius.

It is within the latter Greenfield project that EverGen Infrastructure could stand to make its fortunes. Project Radius, located in southern Ontario, is a late-development-stage portfolio of three high-quality, on-farm RNG projects, collectively capable of producing ~1.7 million GJ/year of RNG that will contribute to the reduction of emissions from agricultural operations in southern Ontario. Each of the three projects is expected to produce ~550,000 GJ/year and will be constructed throughout 2023 and 2024.

“The acquisition of Project Radius provides a foothold in Ontario – a new and strategic jurisdiction in which EverGen can continue to participate in the consolidation and growth of the RNG industry in the near-term, as well as benefit from project economics in line with or exceeding those we have seen with our initial projects,” said Chase Edgelow, CEO of EverGen (https://ibn.fm/VBO5H). “Working alongside Northeast to advance the projects, EverGen will deliver on our platform expansion commitments with the potential to exceed 1,000,000 GJ of RNG production annually.”

For more information, visit the company’s website at www.EverGenInfra.com.

NOTE TO INVESTORS: The latest news and updates relating to EVGIF are available in the company’s newsroom at https://ibn.fm/EVGIF

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all

Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking Forward to 2023 Goals for Patented DehydraTECH(TM) Technology

Lexaria’s 2022 R&D efforts saw high levels of success, establishing the company as one of the world’s leaders in the investigation of CBD for controlling human blood pressure and, separately, demonstrating performance enhancements compared to one of the world’s leading anti-seizure medications
During Q1 2023, Lexaria expects to provide additional results from its hypertension study HYPER-H21-4; complete dosing in the company’s animal dementia and diabetes studies; complete dosing in the human nicotine study NIC-H21-1; and submit and publish additional results in research journals
Lexaria’s DehydraTECH technology currently has 28 granted patents, with many more pending patents in countries worldwide

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is using its patented DehydraTECH(TM) technology to improve the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. In a letter to shareholders last month, Lexaria CEO Chris Bunka provided a thorough strategic update and insight into the company’s plan moving forward.

Mr. Bunka expressed how the current state of the economy has presented challenges to companies, especially during 2022. Still, Lexaria has navigated these challenges well by focusing on the things it can control, such as applied R&D designed to entice others to work with the company commercially. Despite inflation running at a 40-year high and 2022 stock markets experiencing the longest protracted decline since 2008, Lexaria is forging ahead – increasing staff and successfully handling an unprecedented volume of work (https://ibn.fm/K4s9R).

During 2022, Lexaria’s R&D pursuits were a success, firmly establishing the company as one of the world’s leaders in the investigation of cannabidiol (“CBD”) for controlling human blood pressure and demonstrated performance enhancements compared to one of the world’s leading anti-seizure medications. Lexaria expects that 2023 will be full of additional R&D developments.

Lexaria’s expectations for Q1 2023 include the following:

Additional results from hypertension study HYPER-H21-4
Dosing completion in the company’s animal dementia study
Dosing completion in the company’s animal diabetes study
Dosing completion in human nicotine study NIC-H21-1
Submissions and publishing of additional results in research journals

Also in 2023, Lexaria expects to file its Investigational New Drug (“IND”) application and receive approval from the US Food and Drug Administration (“FDA”) to commence the IND clinical study. The study will be a major step in the company’s maturation as a pharmaceutical company and will be its primary research focus once it commences.

Lexaria’s DehydraTECH technology currently has 28 granted patents, with many more pending patents in countries worldwide. The technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine, and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. It is suitable for use with a wide range of product formats, including pharmaceuticals, nutraceuticals, consumer packaged goods, and over-the-counter capsules, pills, tablets, oral suspensions and more.

DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients – increasing effectiveness and improving the way APIs enter the bloodstream. The benefits of DehydraTECH include faster delivery of the drug, increased bioavailability, increased brain absorption, improved drug potency, reduced drug administration costs, and masks unwanted taste, removing the need for additional sweetening ingredients.

Since 2016, Lexaria’s DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and, reduce the time of onset from one to two hours to just minutes.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About MissionIR

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all

USMCA Developed to Bolster North American Export Services, with Freight Technologies Inc. (NASDAQ: FRGT) to Capitalize on It

Export services under NAFTA, mainly covering transportation, travel, business, and financial services, increased from $14.7 billion in 1999 to $30.4 billion in 2021
With the transition from NAFTA to USMCA, trade in goods and services is set to see a spike from 2022 going forward, and Fr8Tech expects to capitalize on this
Freight Technologies Inc., with its superior freight platform for North American cross-border shipping, yielded a 45% YOY revenue growth for Q2 2022, which it looks to surpass in the subsequent quarters of the current financial year
With trucks moving about 70% of North American surface trade by value, trucking companies, Fr8Tech included, are set to be the biggest beneficiaries with the USMCA, enjoying benefits such as reduced administrative burdens and faster shipping times
The USMCA’s objective is to support a mutually beneficial trade that seeks to achieve more accessible markets, fairer trade, and economic growth in North America. Fr8Tech looks to capitalize on opportunities that present themselves to not only create shareholder value but also grow its brand equity and realize its short-term and long-term objectives

According to the United States Census Bureau, the export of services under the North American Free Trade Agreement (“NAFTA”), mainly covering transportation, travel, business, and financial services, increased from $14.7 billion in 1999 to $30.4 billion in 2021. The same applies to the trade of services between the U.S. and Canada. With the transition from NAFTA to the United States-Mexico-Canada Agreement (“USMCA”), it is projected that trade in goods and services in the region will not be altered. The study projects that operations in this sector will soar as trade among the three countries grows (https://ibn.fm/2BEFI).

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), an enterprise developing solutions to optimize and automate the supply chain process and offering a platform for B2B cross-border shipping in the NAFTA (now USCMA) region looks to capitalize not just on the smooth transition, but also the relatively unaltered trade in goods and services to grow its market share and achieve its revenue objectives. This level of focus has allowed the company to achieve a 45% year-over-year (“YOY”) revenue growth for the second quarter of the 2022 financial year, which It looks to surpass in the subsequent quarters of the current financial year (https://ibn.fm/IDih3).

The shift from NAFTA to USMCA came in the wake of proposed amendments to the initial agreement among the member countries. These changes would be founded on the basic principles of free trade provided in NAFTA but modernizing and adjusting some components. For some sectors, particularly the energy sector, the proposed changes received heavy politicization and significant proposed adjustments. However, the transport sector was set to receive more support from the member states. The primary beneficiaries would be logistics services companies and transport modes, who would enjoy a reduced administrative burden and faster shipping times, translating into more revenues and fewer overheads.

With trucks moving about 70% of North American surface trade by value, trucking companies are set to be the biggest beneficiaries with the USMCA (https://ibn.fm/nCMq0). Fr8Tech, with its Fr8App, a B2B marketplace powered by Artificial Intelligence (“AI”) and Machine learning, looks to make cross-border shipping simple, safe and affordable. With the USMCA, the company looks to scale up its operations, grow its customer base and achieve even more growth going forward.

The objective for USMCA, as was the case with NAFTA, is to support mutually beneficial trade leading to more accessible markets, fairer trade, and robust economic growth in North America. It is specifically intended to grow various regional industries and sectors, and transportation is one of this transition’s primary beneficiaries. Fr8Tech recognizes this opportunity and is looking to bank on it to create shareholder value, grow its brand equity, and realize its short-term and long-term objectives.

For more information, visit the company’s website at www.Fr8Technologies.com.

NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT

Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com

About MissionIR

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all